Excess adiposity is commonly associated with insulin resistance, which can increase the risk of cardiovascular disease. However, the exact molecular mechanisms by which obesity results in insulin resistance are yet to be understood clearly. The intracellular nutrient-sensing protein, mechanistic target of rapamycin (mTOR), is a crucial signalling component in the development of obesity-associated insulin resistance. Given that increased tissue activation of mTOR complex-1 (mTORC1) occurs in obesity, diabetes and ageing, we hypothesized that pharmacological inhibition of mTORC1 would improve metabolic dysregulation in diet-induced obesity. We administered continuous rapamycin, a specific mTORC1 inhibitor, orally to C57BL/6J mice concurrently with a high-fat, high-sucrose (HFHS) diet for 20 weeks. The control group received placebo microcapsules. Rapamycin-treated mice showed significantly reduced weight gain and adiposity (33.6 ± 4.9 versus 40.4 ± 3.0% body fat, P < 0.001, n = 8 mice per group), despite increased or equivalent food intake compared with the placebo group. The rapamycin-fed mice also demonstrated reduced plasma glucose (252 ± 57 versus 297 ± 67 mg dl −1 , P < 0.001) and improved insulin sensitivity during insulin and glucose tolerance testing. Rapamycin-treated mice also had lower plasma triglycerides (48 ± 13 versus 67 ± 11 mg/dL, P < 0.01) and hepatic triglyceride content (89 ± 15 versus 110 ± 19 mg/g liver, P < 0.05) compared with the placebo group. A moderately low dose of rapamycin decreased adiposity and improved the metabolic profile in a model of diet-induced obesity. These data suggest that low-grade chronic mTORC1 inhibition might be a potential strategy for anti-obesity therapies.
has been observed (Khamzina, Veilleux, Bergeron, & Marette, 2005; Korsheninnikova et al., 2006) . Deletion of the adipocyte-specific mTORC1 protein Raptor results in mice that are lean and insulin sensitive with enhanced fatty acid oxidation (Polak et al., 2008) ; likewise, whole-body deletion of S6K1, the downstream substrate of mTORC1, improves insulin sensitivity and extends lifespan in mice (Selman et al., 2009; Um et al., 2004) . These findings suggest that mTORC1 plays an important role in regulation of insulin sensitivity.
Thus, it would be predicted that pharmacological inhibition of mTORC1 might have important implications for glucose homeostasis and that rapamycin, an mTORC1 inhibitor, would act in a similar manner.
Given that mTORC1 activity is increased in obesity and diabetes, its inhibition in chronic metabolic disease offers an attractive therapeutic opportunity. Rapamycin (sirolimus), a widely used immunosuppressant (Cruzado, 2008) , is primarily a specific mTORC1 inhibitor and could be anticipated to mimic the beneficial metabolic effects of longevity.
However, the clinical use of rapamycin in transplantation is plagued with significant metabolic dysregulation, including hyperlipidaemia and hyperglycaemia, and its effects on the immune system are complex (Morrisett et al., 2002; Teutonico, Schena, & Di Paolo, 2005) . In rodent models, rapamycin has been used to evaluate effects on glucose tolerance, with conflicting results so far. Many published studies have clearly demonstrated that rapamycin administration leads to the development of hyperglycaemia, increased insulin levels and glucose intolerance (Aggarwal, Fernandez, & Soliman, 2006; Chang et al., 2009b; Cunningham et al., 2007; Fraenkel et al., 2008; Houde et al., 2010; Paschoal et al., 2017; Yang et al., 2012) . Likewise, it is well established that transplant subjects receiving rapamycin develop abnormal metabolic profiles (Johnston, Rose, Webster, & Gill, 2008; Teutonico et al., 2005) . However, a handful of studies have shown that rapamycin improves glucose metabolism in mice (Deepa et al., 2013; Makki et al., 2014; Reifsnyder, Flurkey, Te, & Harrison, 2016) . Nevertheless, low-dose rapamycin has been shown consistently to extend lifespan in older mice in several studies (Anisimov et al., 2011; Harrison et al., 2009; Miller et al., 2011; Neff et al., 2013) and to abolish cognitive defects in a mouse model of Alzheimer's disease (Lin et al., 2017; Spilman et al., 2010) , suggesting that mTORC1 inhibition might be beneficial in the appropriate setting.
Nutrient overabundance is associated with increased mTORC1 activity in insulin-sensitive tissues, including liver and muscle (Korsheninnikova et al., 2006) . Thus, we hypothesized that the metabolic consequences of overnutrition can be improved by mild suppression of mTORC1 activity. Therefore, in the present study, we examined the effects of chronic pharmacological inhibition of mTORC1 using oral rapamycin administered at a low-to-moderate dose concurrently with a high-fat, high-sucrose (HFHS) diet. We used C57BL/6 mice, which are susceptible to excessive weight gain when fed diets rich in refined sugar and saturated fat. We show here that chronic oral rapamycin does not induce hyperglycaemia or hyperlipidaemia, but in fact has beneficial effects on the metabolic abnormalities that accompany obesity in this model.
New Findings
• What is the central question of this study?
Whether chronic oral rapamycin promotes beneficial effects on glucose/lipid metabolism and energy balance when administered to mice with an obesogenic diet rich in saturated fat and sucrose has not been explored.
• What is the main finding and its importance?
Chronic oral rapamycin reduces body weight and fat gain, improves insulin sensitivity and reduces hepatic steatosis when administered to mice with a high-fat, high-sucrose diet. In addition, we make the new observation that there appear to be tissue-specific effects of rapamycin.
Although rapamycin appears to impart its effects mainly on visceral adipose tissue, its effects on insulin sensitivity are mediated by subcutaneous adipose tissue.
METHODS

Ethical approval
All experimental procedures in mice were undertaken with approval from the Institution Animal Care and Use Committee of the University of Washington (protocol #3104-01 03/15/13 -02/28/19) and followed the guidelines of the US National Institutes of Health (NIH) (NIH publication no. 8023, revised 1978) . Pain and suffering were kept to a minumim whenever possible. The work described herein complies with the animal ethics principles maintained by the journal.
Guide for the Care and Use of Laboratory Animals
Animals and diet
C57BL/6J male mice were obtained commercially (Jackson Laboratories, Sacramento, CA, USA) and were fed an HFHS diet (Bio-Serv F1850, Frenchtown, NJ, USA) ad libitum starting at age 10 weeks for 20 weeks. This diet provides 36% fat as lard and 36%
carbohydrates as sucrose and thus 60% total calories from fat.
Micro-encapsulated oral rapamycin (obtained from Dr Randy Strong, University of Texas, San Antonio, TX, USA), at the dose of 14 p.p.m.
(2.24 mg kg −1 day −1 ) as described by Harrison et al. (2009) or empty microcapsules for placebo (n = 10 mice per group) were incorporated in the diets (Bio-Serv). Mice were group housed (four or five mice per cage), randomized into treatment groups, and maintained in a temperature-and light-controlled specific pathogen-free facility with ad libitum access to food and water on a 12 h-12 h standard light-dark cycle. Body weights were measured weekly. Food intake was recorded after 5, 9 and 13 weeks of diet and calculated as an average of three sequential days from a known amount of food given.
The food was reweighed daily and the amount of food consumed calculated. At the end of the experiment, mice were anaesthetized by continuous isoflurane inhalation, ∼1 ml of blood was collected through the retro-orbital sinus, and the mice were killed by cervical dislocation while still under continuous isoflurane anaesthesia. After perfusion of phosphate-buffered saline through the left ventricle, harvested epididymal white adipose tissue, inguinal white adipose tissue and liver were snap-frozen in liquid nitrogen and stored at −80 • C or were fixed with 10% neutral-buffered formalin and embedded in paraffin wax.
Analytical procedures
Metabolic variables were measured in blood samples (50-100 l), collected every 4 weeks and during oral glucose tolerance tests (GTTs), that were obtained from the retro-orbital sinus after a 4 h fast during the light cycle in mice that had been anaesthetized using isoflurane inhalation. Consecutive bleeds involved alternate eyes, and ocular hydration gel was applied to both eyes before termination of general anaesthesia. Whole-blood rapamycin concentrations were measured from 200 l of blood by HPLC at the Nutrition and Obesity
Research Center of the University of Washington. Whole blood glucose was measured using a One Touch Ultra glucometer (Life Scan, Milpitas, CA, USA). Cholesterol, triglycerides and free fatty acids in plasma were measured using colorimetric assay kits within 24h of collection. Lipoprotein classes were separated from pooled plasma samples by fast-phase liquid chromatography (FPLC). Plasma insulin and serum amyloid A (SAA) levels were measured using enzymelinked immunosorbent assay as previously described (Subramanian et al., 2008) . Hepatic triglyceride content was determined after lipid extraction using the Folch method (Folch, Lees, & Sloane Stanley, 1957) . Intraperitoneal glucose (1 mg kg −1 ) and insulin (0.75 U kg −1 ) tolerance tests were performed after a 4 h fast as described previously (Subramanian et al., 2008) . Body composition was measured non-invasively in conscious immobilized mice (n = 7-8 mice per group) using quantitative magnetic resonance (EchoMRI whole body composition analyser; Echo Medical Systems, Houston, TX, USA) by the University of Washington Nutrition Obesity Research Center Energy Balance Core, as described previously (den Hartigh et al., 2017) . All analyses were performed in a blinded manner.
Real-time PCR
Total RNA was extracted from ∼100 mg of whole adipose tissue or liver using a commercially available RNA extraction kit according to the manufacturer's protocol (Agilent Technologies, Santa Clara, CA, USA). After spectroscopic quantification, 2 g of RNA was reverse transcribed, and the complementary DNA thus obtained was analysed by real-time quantitative PCR by standard protocols using an ABI 7900HT instrument. Primer and probe sets for individual genes were purchased from Applied Biosystems (Assay-on-Demand, Life Technologies, Carlsbad, CA, USA). GAPDH was used as the control housekeeping gene. Relative amounts of the target gene were calculated using the ΔΔCt formula.
Histology and immunohistochemistry
Formalin-fixed, paraffin-embedded adipose tissues were used.
Macrophages in adipose tissue were detected using a rat monoclonal antibody (Mac2; titre 1:2500; Cedarlane Laboratories, Burlington, NC, USA). Liver sections were stained with Masson's Trichrome using standard protocols. Adipocyte cross-sectional area was measured as previously described (Subramanian et al., 2008 ). 
Immunoblotting
Statistical analyses
Sample sizes were determined using power calculations from previous studies evaluating weight gain in C57Bl/6 mice fed an HFHS diet. In order to see more than twofold significant differences at 90% power with = 0.05, we used 10 mice per group. Data were analysed using the GraphPad Prism 6 program (GraphPad Software Inc., La Jolla, CA, USA) and are presented as means ± SD. Student's t test (two-tailed) or two-way ANOVA was used to detect differences between groups and across multiple time points, as appropriate. A P value <0.05 was considered statistically significant.
RESULTS
Rapamycin administered chronically with an HFHS diet decreases weight gain and adiposity
We first evaluated the effects of a low-to-moderate oral dose of rapamycin on weight gain. C57BL/6J mice were placed on an HFHS diet admixed with rapamycin or placebo for 20 weeks. The dose of rapamycin used was that which has been shown to prolong lifespan in mice (Harrison et al., 2009; Miller et al., 2014) . Mice appeared healthy and tolerated rapamycin. We confirmed that rapamycin concentrations were detectable in the blood of mice that received the drug at 2-4 weeks (Figure 1a ). Mice that received dietary rapamycin gained less Open bars, placebo-fed mice; filled bars, rapamycin-fed mice. Data are presented as mean ± standard deviation. n = 7-10 per group. * P < 0.05, ** P < 0.01, *** P < 0.001 versus placebo weight compared with placebo-fed HFHS-fed animals ( Figure 1b) . The lesser degree of weight gain was noticeable at 8-10 weeks on diets and occurred despite increased or equivalent food intake in the animals that received rapamycin (Figure 1c ). Body composition analysis revealed decreased generalized body fat distribution in rapamycinfed mice without differences in lean body mass (Figure 1d ,e). The difference in body fat was not attributable to changes in epididymal fat pad size, which were not different between the two groups (not shown), suggesting that the difference in adiposity was probably attributable to differences in other fat depots.
Chronic rapamycin treatment with an HFHS diet improves metabolic abnormalities associated with obesity
Given that rapamycin causes lipid abnormalities when administered in the clinical setting (Kasiske et al., 2008) 
Adipose tissue inflammation is not altered in obese mice with chronic rapamycin treatment
Given that adipose tissue macrophage accumulation is a crucial feature in obesity, we examined whether rapamycin treatment influenced macrophage recruitment to adipose tissue. Adipocyte size was not different between the rapamycin and placebo groups in epididymal (Figure 3b) . Expression of the adipokine adiponectin was increased in whole epididymal adipose tissue, but no differences were observed in macrophage or chemokine gene expression patterns in epididymal fat pads (Figure 3c ). However, in inguinal fat we observed a decrease in the chemotactic genes Ccl2 and Saa3, in addition to increased expression of Ucp1 and Cidea, genes associated with browning of adipocytes (Figure 3d,e) .
Rapamycin reduces hepatic steatosis without affecting inflammation during diet-induced obesity
Changes in the liver often accompany those seen in adipose tissue with diet-induced obesity. Therefore, we next determined whether rapamycin affects hepatic steatosis and inflammation in diet-induced obesity. Liver weights showed a downward trend in the rapamycinfed animals but did not reach statistical significance (Figure 4a ).
Hepatic triglyceride content was decreased in the mice that received rapamycin (P < 0.05; Figure 4b ). Correspondingly, hepatic steatosis was significantly decreased in the rapamycin-fed animals compared with placebo-fed animals (Figure 4c ). There was no evidence of overt liver toxicity in the rapamycin-fed animals as evidenced by alanine aminotransferase (ALT) measurements, which showed a downward trend in the rapamycin group, but did not reach statistical significance (Figure 4d) . Levels of the circulating liver-derived inflammatory protein SAA were also unchanged (Figure 4e) , and gene expression analysis did not reveal evidence of adverse effects on genes involved in gluconeogenesis, lipogenesis or inflammation (Figure 4f ).
Effects of rapamycin on tissue signalling through mTORC1/S6K1
To evaluate the tissue effects of rapamycin in HFHS feeding, we evaluated the phosphorylation status of the mTORC1 effector p70 S6 kinase 1 (S6K1) in epididymal white adipose tissue and liver (Figure 6a,b) . These findings suggest that the observed effects of rapamycin on epididymal white adipose tissue might be attributable to signalling through S6K1 without an effect on signalling through Akt or rictor, whereas inguinal white adipose tissue plays a role in the resolution of insulin resistance.
DISCUSSION
In the present study, we show that chronic oral rapamycin, when administered at a low-to-moderate dose with a high-fat, high-sucrose diet, decreased weight gain and had modest beneficial effects on lipid and glucose metabolism. The goal of our study was to evaluate whether rapamycin administered concurrently with an HFHS diet would result in improvement in the metabolic dysregulation that accompanies obesity. Here, we found that chronic rapamycin administration did not result in worsening of metabolic complications as has been demonstrated in other published studies and, in fact, led to modest improvements in body weight, triglycerides and glucose metabolism. mTORC1 is highly activated in insulin-sensitive tissues of obese and high-fat-fed rodents (Khamzina et al., 2005; Tremblay et al., 2005; Um et al., 2004) . Thus, inhibition of mTORC1 is an attractive possibility for drug targeting to decrease weight gain and its antecedent metabolic deregulation. Rapamycin, an inhibitor of mTORC1, has been evaluated in this context, but its effects on glucose and lipid metabolism are conflicting. Clinically, given that rapamycin is widely used to prevent graft rejection in transplant recipients, there is an extensive body of literature evaluating its side-effects; thus, it is well known that metabolic abnormalities, such as hyperlipidaemia and hyperglycaemia, often accompany rapamycin treatment. However, in most (Paschoal et al., 2017) . Likewise, oral rapamycin administered to aged hybrid mice demonstrated impaired glucose tolerance after 4 weeks of rapamycin feeding (Yang et al., 2012) . In the same study, I.P. rapamycin given to 2-month-old C57BL6 mice for 3 weeks worsened glucose tolerance on a chow diet, with a decrease in islet size. In contrast, in line with our own observations, a study that administered chronic weekly rapamycin injections for 22 weeks improved insulin sensitivity and reduced adipocyte size, but no body weight data were presented (Makki et al., 2014) . Likewise, recent studies in genetically obese F I G U R E 5 Effects of chronic rapamycin on mTORC signalling in adipose tissue and livers of obese mice. Phosphorylation status of p70S6K1, S6, Akt and total rictor (a component of mTORC2) were immunoassayed in tissue lysates prepared from mice consuming HFHS diets containing microencapsulated rapamycin (Rapa) or placebo (P). Animals were fasted overnight (∼16 h) and injected with insulin (1 IU kg −1 ) before they were killed. Epididymal white adipose tissue (a,b) and liver (c,d) were harvested 10 min after insulin injection. Saline was injected as a control in some mice (as depicted in the figure). Tubulin was probed to assess the adequacy of protein loading. Open bars, placebo-fed mice; filled bars, rapamycin-fed mice. Data are presented as mean ± standard deviation. ** P < 0.01, ** P < 0.01 versus placebo mice fed rapamycin in a chow diet, at a dose similar to that in our study, lost significant body weight and fat mass (Deepa et al., 2013) and showed improvements in cardiovascular function (Reifsnyder et al., 2018) . In mouse models of type 2 diabetes, including TALLYHO, BKS-db/db and NcZ10, chronic rapamycin treatment also improved insulin resistance and promoted weight loss (Reifsnyder et al., 2016) .
Rapamycin has also been evaluated in the setting of high-fat diets.
High-fat-fed KK/HIJ mice given I.P. rapamycin treatments for 42 days had decreased adiposity with worsened glucose tolerance (Chang et al., 2009b) . Despite this, the authors observed a decrease in hepatic steatosis with rapamycin treatment, again similar to our own findings.
The same authors also conducted a separate study in C57BL/6 mice and demonstrated that rapamycin decreased adiposity without worsening of hyperglycaemia, but they did not evaluate glucose homeostasis (Chang et al., 2009a) . In a small study of healthy human subjects, a single, low-dose administration of rapamycin improved skeletal muscle glucose uptake after amino acid infusion without affecting lipids or glucose (Krebs et al., 2007) . In mice, deletion of whole-body S6K1, the downstream mTORC1 target, results in extended lifespan (Selman et al., 2009) , prevents diet-induced obesity (Um et al., 2004 ) and improves -cell survival in conditions of chronic hyperglycaemia (Pende et al., 2000) . However, adipocyte-specific mTORC1 deletion results in resistance to diet-induced obesity, but with worsened hepatic steatosis and glucose metabolism (Xiong, Xu, Wang, Kuang, & Shan, 2018) . Thus, results from previous studies are variable, and discrepancies could be attributed to the different models used, route, dose and duration of drug administration and, possibly, environmental factors. The present study contributes to accumulating knowledge regarding the beneficial effects of moderate chronic mTORC1 suppression, now, for the first time, in a mouse model of diet-induced obesity with associated features resembling human metabolic disease.
There are several important findings in our study that are different from the existing literature. We used chronic dietary encapsulated rapamycin given at a low-to-moderate dose, which obviates potential adverse effects on I.P. administration and is therefore more clinically relevant. We also used the same dose that has been shown unequivocally to prolong lifespan (Harrison et al., 2009; Miller et al., 2014) . Another group has shown that C57Bl/6J mice given the same dose of encapsulated rapamycin admixed into a high-fat diet for 4 months showed worsened glucose tolerance and increased adiposity (Liu et al., 2014) . We did not observe worsening of glucose or insulin tolerance in rapamycin-fed obese mice over those observed in the placebo-fed animals; it is F I G U R E 6 Effects of chronic rapamycin on mTORC signalling in subcutaneous adipose tissue of obese mice. (a,b) Phosphorylation status of p70S6K1, S6, Akt and total rictor (a component of mTORC2) were immunoassayed in tissue lysates prepared from mice consuming HFHS diets containing microencapsulated rapamycin (Rapa) or placebo (P). Animals were fasted overnight (∼16 h) and injected with insulin (1 IU kg −1 ) before they were killed. Inguinal white adipose tissue was harvested 10 min after insulin injection. Saline was injected as a control in some mice (as depicted in the figure) . Tubulin was probed to assess the adequacy of protein loading. Open bars, placebo-fed mice; filled bars, rapamycin-fed mice. * P < 0.05, *** P < 0.001 versus placebo possible that in the context of higher levels of insulin resistance, as is the case with our mice and is reminiscent of human obesityassociated metabolic disease, rapamycin exerts beneficial effects on glucose metabolism. In fact, we observed an improvement in hyperglycaemia and in insulin sensitivity. This dose also did not inhibit mTORC2, recently implicated in rapamycin-induced insulin resistance (Lamming et al., 2012) . Importantly, our findings suggest that in the setting of hyperglycaemia and high levels of insulin resistance, administration of rapamycin does not adversely disrupt glucose homeostasis.
Dyslipidaemia, manifested as hypertriglyceridaemia and hypercholesterolaemia, is commonly associated with rapamycin (sirolimus).
However, rapamycin is seldom administered as monotherapy but usually in conjunction with other immunosuppressants, such as glucocorticoids, which also induce insulin resistance and dyslipidaemia.
Several studies have failed to show worsened lipid abnormalities.
Administration of rapamycin by oral gavage three times a week prevented the development of type 1 diabetes in NOD mice, without causing dyslipidaemia (Baeder, Sredy, Sehgal, Chang, & Adams, 1992) .
In our studies, we did not observe worsening of hypercholesterolaemia or free fatty acid concentrations and demonstrated an improvement in triglyceride concentrations.
Hepatic steatosis is a common accompaniment in obesity and type 2 diabetes, and mTORC1 plays a known role in hepatic lipogenesis (Porstmann et al., 2008) . Liver-specific deletion of S6 kinase 1, the effector protein of mTORC1, resulted in decreased hepatic steatosis (Bae et al., 2012) . In our study, rapamycin decreased liver triglyceride accumulation, without detectable differences in lipogenic or fatty acid oxidative genes, although we did observe an upward trend in concentrations of circulating free fatty acids. Recent work has shown that mTORC1 plays an important role in the regulation of phosphocholine cytidylyltransferase , the rate-limiting step in phosphatidylcholine synthesis, thus acting as a major regulator of hepatic triglyceride production (Quinn et al., 2017) . This suggests that rapamycin could lower plasma triglycerides and improve hepatic steatosis by reducing phospholipid biosynthesis.
In our study, we also observed reduced weight gain and adiposity in rapamycin-fed animals despite equivalent food intake. There were no differences in perigonadal fat pad weights between the groups, suggesting that differences in other fat pads, such as subcutaneous and retroperitoneal depots, might have accounted for the differences. The difference in weight might be related to increased energy expenditure, although we did not perform oxygen-consumption studies. Evidence of enhanced expression of Ucp1 and Cidea, genes characteristic of brown fat, suggests that adaptive thermogenesis might be increased in rapamycin-treated animals and could account, in part, for the differences in weight gain. Recent studies suggest conflicting effects of mTORC1 inhibition on white adipose tissue browning. Although the increase in white adipose tissue Ucp1 expression observed herein has previously been suggested in mice deficient in adipocyte mTOR (Shan et al., 2016) , several recent studies suggest the opposite. A study of mice fed a chow diet containing 42 p.p.m. encapsulated rapamycin for 2 weeks exhibited reduced thermogenic gene expression and worsened glucose tolerance (Tran et al., 2016) , whereas studies by Liu and colleagues likewise observed decreased Ucp1 expression with 4-5 mg kg −1 rapamycin treatment (Liu et al., 2016; Liu, Ceddia, & Collins, 2018) . Notably, these studies used acute rapamycin treatment at a dose that was two to three times higher than in the present study, suggesting important effects of the dose and duration of treatment with rapamycin that require additional study. We also did not see any effects on adipocyte size, although others have demonstrated decreased adipocyte size with rapamycin treatment (Polak et al., 2008; Um et al., 2004) . Macrophages have been implicated as key players in contributing to insulin resistance in obesity. Although rapamycin is known to affect differentiation and trafficking of a variety of immune cells, including macrophages (Thomson, Turnquist, & Raimondi, 2009 ), we did not see prominent effects on local inflammation in adipose tissue or liver in rapamycin-treated mice. These findings suggest that the weight differences observed are not secondary to differences in macrophage infiltration within adipose tissue. However, recent work suggests that genetic inhibition of macrophage mTORC1 leads to improvements in high-fat diet-induced insulin resistance and inflammation (Jiang, Westerterp, Wang, Zhu, & Ai, 2014) , suggesting a potential role for macrophages in mediating the beneficial effects of chronic low-dose rapamycin. Overall, the phenotype of these rapamycin-fed mice is reminiscent of the phenotype of the adiposespecific raptor knockout mouse (Polak et al., 2008) .
Rapamycin concentrations were detectable in the blood in the experimental animals, but at levels lower that what has been reported previously in similar studies, with only partial inhibition of S6K1. The reasons for this are unknown, but might be the result of inhibitory effects of the added dietary sucrose or alterations to the gut microbiota that modulated rapamycin absorption. Low blood rapamycin concentrations are probably not attributable to suboptimal timing of blood sampling, because the half-life of rapamycin in the blood of mice is ∼15 h (Arrioloa Apelo et al., 2016) . It is striking that rapamycin could promote metabolic benefits, despite modest inhibition of mTOR.
Thus, the notion of optimal mTOR inhibition has been put forth.
It is conceivable that a low dose of rapamycin could potentially improve the tissue metabolic milieu by normalizing, but not completely inhibiting, mTORC1 signalling (Laplante & Sabatini, 2012 ). This dose could also limit the complex feedback mechanisms involved in the activation of IRS1-PI3K-Akt and the inhibition of mTORC2-Akt induced by high-dose rapamycin treatment and still allow for sufficient adaptive thermogenesis. Thus, too much or too little mTOR activity might negatively influence tissue metabolism. Indeed, a recent study showed that I.P. rapamycin administered intermittently at a low dose improved body weight and plasma triglyceride concentrations with no measurable changes in glucose metabolism and with minimal evidence of mTOR inhibition (Leontieva, Paszkiewicz, & Blagosklonny, 2014) , supporting the notion that moderate mTOR inhibition might impart metabolic benefit. Alternatively, in the present study, rapamycin delivered orally in microcapsules could have generated byproducts with off-target effects, as evidenced by the lack of inhibition of downstream target S6K1 in inguinal white adipose tissue and liver, or by acting through the gut microbiota. Interestingly, in the present study rapamycin inhibited phospho-S6K1 in epididymal white adipose tissue only during acute insulin activation, suggesting mild insulin resistance in this depot, but improved insulin sensitivity of inguinal white adipose tissue without any measurable changes in phospho-S6K1 in that depot.
This suggests a complex interplay between potentially different target and effector tissues of rapamycin that requires further exploration.
Future studies could directly compare the oral delivery method used herein with the commonly used I.P. or S.C. rapamycin delivery to evaluate whether distinct mechanisms of action explain the observed tissue-specific effects.
In summary, we have demonstrated that a chronic low-to-moderate oral dose of rapamycin does not worsen but instead beneficially modulates metabolic abnormalities during the course of diet-induced obesity. Our study has important clinical implications for the treatment of chronic disease states such as diabetes, Alzheimer's disease and cancer and for healthy lifespan extension. Although rapamycin itself is plagued with metabolic side-effects in the clinical setting, pharmacological strategies that provide optimal titration of mTORC1 activity have therapeutic potential to improve the tissue metabolic milieu in obesity and diabetes.
